Acute Myeloid Leukemia AML Market is driven by targeted therapy advancements
The acute myeloid leukemia (AML) market encompasses a comprehensive range of therapeutic and diagnostic solutions designed to manage this aggressive hematological malignancy. Core products include cytarabine-based chemotherapies, FLT3 and IDH inhibitors, monoclonal antibodies, immune checkpoint inhibitors, and supportive care agents such as growth factors and antiemetics. Advances in...
0 Comments 0 Shares 60 Views 0 Reviews